The chairman of the board at Biogen has purchased more than $3 million worth of shares in the company, marking the first time a director or executive has bought the company’s shares at market price in five years. Stelios Papadopoulos, a retired investment banker who has served on the board of Cambridge drugmaker Biogen (Nasdaq: […]

Merck & Co. (MRK) enhanced its oncology pipeline with the $605 million acquisition of privately-held Israeli biotech company cCam Biotherapeutics, which is focused on the development of cancer immunotherapies.   With the acquisition of the five-year-old cCam, Merck will add that company’s lead product CM-24, a monoclonal antibody (mAb) that targets CEACAM1, a “checkpoint” protein […]

Twenty-seven years ago George Yancopoulos was a scientific superstar, a professor of biology at Columbia at age 28. But his father, a first-generation Greek immigrant, kept complaining about how little academia paid. So Yancopoulos, now 55, signed on with a nascent Tarrytown, N.Y.-based biotech firm called Regeneron–and has since led the invention of four approved […]

French drugmaker Sanofi (SASY.PA) said on Tuesday it was committing up to $2.17 billion to a collaboration with its long-time partner Regeneron Pharmaceuticals (REGN.O) in the hot area of cancer immunotherapy. Sanofi will make an upfront payment of $640 million to Regeneron and the U.S. biotech company will get up to $375 million more if certain […]

The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being adequately controlled by existing drugs called statins. It might be a big step in the battle against heart disease – and […]

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.S. Food and Drug Administration (FDA) approved AbbVie’s TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) tablets in combination with ribavirin (RBV) for the treatment of non-cirrhotic adults with genotype […]

Venture-backed biotechs continue their blistering pace of funding. According to the latest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters, over $2.1B was invested in biotech companies in 2Q 2015, bringing the year to date total to almost $4B(covered here, here). Four of the last five quarters are amongst the largest record-setting […]

Merck & Co. has apparently gotten excited again about pushing the frontier with new RNA-based therapies. MRL Ventures, Merck’s early-stage biotech investment arm, has agreed to join The Baupost Group in leading a $55 million Series B venture investment in Cambridge, Mass.-based RaNA Therapeutics. The round included a handful of “crossover” investors that usually focus […]

An appeals court ruled that Novartis AG could begin the first U.S. sales of a knockoff biotech drug on Sept. 2, a key step in efforts to contain spending on high-cost therapies through lower-priced competition. The ruling Tuesday by the U.S. Court of Appeals for the Federal Circuit in Washington came on the same day […]

Novartis AG must wait until Sept. 2 to sell the first biosimilar drug to be approved in the United States, a copycat version of Amgen Inc’s $1.2 billion-a-year Neupogen, a U.S. appeals court said on Tuesday. The ruling stemmed from a lawsuit Amgen filed last October in federal court in San Francisco in which it […]